Common Stocks - 98.3%
|
|||
Shares
|
Value ($)
|
||
Biotechnology - 16.0%
|
|||
Biotechnology - 16.0%
|
|||
ADC Therapeutics SA (a)(b)
|
988,800
|
6,763,392
|
|
Agios Pharmaceuticals, Inc. (a)
|
700,000
|
13,629,000
|
|
Alnylam Pharmaceuticals, Inc. (a)
|
600,000
|
75,480,000
|
|
Ambrx Biopharma, Inc. ADR
|
354,700
|
1,393,971
|
|
Arcutis Biotherapeutics, Inc. (a)
|
692,821
|
14,466,102
|
|
Argenx SE ADR (a)
|
540,000
|
167,022,000
|
|
Ascendis Pharma A/S sponsored ADR (a)
|
954,412
|
80,657,358
|
|
Atara Biotherapeutics, Inc. (a)
|
1,650,000
|
8,580,000
|
|
Avid Bioservices, Inc. (a)
|
1,000,000
|
13,370,000
|
|
Beam Therapeutics, Inc. (a)(b)
|
400,000
|
14,072,000
|
|
BeiGene Ltd. ADR (a)
|
120,000
|
16,466,400
|
|
Blueprint Medicines Corp. (a)
|
559,700
|
30,783,500
|
|
Celldex Therapeutics, Inc. (a)
|
646,599
|
15,208,008
|
|
Century Therapeutics, Inc.
|
815,000
|
7,082,350
|
|
Cerevel Therapeutics Holdings (a)
|
1,280,000
|
33,446,400
|
|
Cytokinetics, Inc. (a)
|
1,726,438
|
68,884,876
|
|
Denali Therapeutics, Inc. (a)
|
650,000
|
15,788,500
|
|
Erasca, Inc. (b)
|
2,500,000
|
13,550,000
|
|
Exelixis, Inc. (a)
|
1,500,000
|
27,495,000
|
|
Fate Therapeutics, Inc. (a)(b)
|
350,000
|
8,085,000
|
|
Generation Bio Co. (a)(b)
|
509,353
|
2,862,564
|
|
Graphite Bio, Inc.
|
800,000
|
1,880,000
|
|
Imago BioSciences, Inc.
|
200,000
|
3,232,000
|
|
Innovent Biologics, Inc. (a)(c)
|
7,800,000
|
24,203,538
|
|
Instil Bio, Inc. (a)(b)
|
1,500,000
|
9,007,500
|
|
Intellia Therapeutics, Inc. (a)
|
500,000
|
23,070,000
|
|
Janux Therapeutics, Inc. (b)
|
500,000
|
5,565,000
|
|
Keros Therapeutics, Inc. (a)
|
460,000
|
15,548,000
|
|
Legend Biotech Corp. ADR (a)
|
900,000
|
38,061,000
|
|
Mirati Therapeutics, Inc. (a)
|
200,000
|
7,832,000
|
|
Morphic Holding, Inc. (a)
|
319,823
|
7,496,651
|
|
Nuvalent, Inc. Class A (a)(b)
|
351,130
|
3,111,012
|
|
Poseida Therapeutics, Inc. (a)
|
1,746,425
|
3,964,385
|
|
PTC Therapeutics, Inc. (a)
|
1,149,600
|
33,763,752
|
|
Regeneron Pharmaceuticals, Inc. (a)
|
315,000
|
209,393,100
|
|
Relay Therapeutics, Inc. (a)(b)
|
1,600,000
|
26,048,000
|
|
Sarepta Therapeutics, Inc. (a)
|
340,000
|
24,758,800
|
|
Scholar Rock Holding Corp. (a)(b)
|
155,315
|
779,681
|
|
Shattuck Labs, Inc. (a)
|
1,162,800
|
3,325,608
|
|
Stoke Therapeutics, Inc. (a)
|
500,000
|
6,055,000
|
|
TG Therapeutics, Inc. (a)
|
1,465,800
|
6,478,836
|
|
uniQure B.V. (a)
|
670,000
|
9,621,200
|
|
Vaxcyte, Inc. (a)
|
790,856
|
18,972,635
|
|
Vertex Pharmaceuticals, Inc. (a)
|
315,000
|
84,624,750
|
|
Verve Therapeutics, Inc.
|
280,000
|
4,244,800
|
|
Xencor, Inc. (a)
|
1,400,000
|
31,262,000
|
|
Xenon Pharmaceuticals, Inc. (a)
|
297,700
|
7,844,395
|
|
Zai Lab Ltd. (a)(d)
|
6,000,000
|
19,038,638
|
|
Zentalis Pharmaceuticals, Inc. (a)
|
1,281,319
|
30,892,601
|
|
1,295,161,303
|
|||
Health Care Equipment & Supplies - 16.7%
|
|||
Health Care Equipment - 16.7%
|
|||
Boston Scientific Corp. (a)
|
12,000,000
|
492,120,000
|
|
Envista Holdings Corp. (a)
|
1,900,000
|
81,776,000
|
|
Hologic, Inc. (a)
|
500,000
|
37,635,000
|
|
Insulet Corp. (a)
|
1,000,000
|
213,480,000
|
|
Intuitive Surgical, Inc. (a)
|
90,000
|
20,487,600
|
|
Masimo Corp. (a)
|
400,000
|
56,172,000
|
|
Novocure Ltd. (a)
|
240,000
|
19,291,200
|
|
Outset Medical, Inc. (a)(b)
|
1,080,000
|
23,544,000
|
|
Penumbra, Inc. (a)
|
1,398,965
|
205,535,938
|
|
PROCEPT BioRobotics Corp. (b)
|
600,000
|
23,472,000
|
|
ResMed, Inc.
|
585,000
|
119,024,100
|
|
Tandem Diabetes Care, Inc. (a)
|
760,000
|
51,809,200
|
|
1,344,347,038
|
|||
Health Care Providers & Services - 28.7%
|
|||
Health Care Facilities - 3.1%
|
|||
Cano Health, Inc. (a)
|
5,400,000
|
27,810,000
|
|
HCA Holdings, Inc.
|
515,000
|
108,356,000
|
|
Rede D'Oregon Sao Luiz SA (c)
|
2,800,000
|
21,103,618
|
|
Surgery Partners, Inc. (a)
|
1,750,000
|
68,600,000
|
|
The Oncology Institute, Inc. (e)
|
2,232,581
|
20,115,555
|
|
245,985,173
|
|||
Health Care Services - 6.7%
|
|||
1Life Healthcare, Inc. (a)(b)
|
1,750,000
|
14,822,500
|
|
agilon health, Inc. (a)(b)
|
5,600,000
|
106,960,000
|
|
Cigna Corp.
|
1,028,000
|
275,802,120
|
|
Guardant Health, Inc. (a)
|
200,000
|
8,196,000
|
|
LifeStance Health Group, Inc.
|
4,250,000
|
31,662,500
|
|
Oak Street Health, Inc. (a)(b)
|
5,650,000
|
106,672,000
|
|
544,115,120
|
|||
Managed Health Care - 18.9%
|
|||
Alignment Healthcare, Inc. (a)(b)
|
3,624,100
|
38,705,388
|
|
Centene Corp. (a)
|
2,300,000
|
187,312,000
|
|
Humana, Inc.
|
845,000
|
383,824,350
|
|
UnitedHealth Group, Inc.
|
1,840,000
|
914,075,202
|
|
1,523,916,940
|
|||
TOTAL HEALTH CARE PROVIDERS & SERVICES
|
2,314,017,233
|
||
Health Care Technology - 1.8%
|
|||
Health Care Technology - 1.8%
|
|||
Definitive Healthcare Corp. (b)
|
500,000
|
9,775,000
|
|
Doximity, Inc. (b)
|
1,000,000
|
34,990,000
|
|
Inspire Medical Systems, Inc. (a)
|
440,000
|
77,805,200
|
|
Medlive Technology Co. Ltd. (c)
|
3,000,000
|
3,417,780
|
|
Phreesia, Inc. (a)
|
900,000
|
16,326,000
|
|
142,313,980
|
|||
Life Sciences Tools & Services - 20.1%
|
|||
Life Sciences Tools & Services - 20.1%
|
|||
10X Genomics, Inc. (a)
|
445,000
|
22,779,550
|
|
10X Genomics, Inc. Class B (a)(c)
|
500,000
|
25,595,000
|
|
Agilent Technologies, Inc.
|
620,000
|
79,087,200
|
|
Avantor, Inc. (a)
|
2,000,000
|
64,080,000
|
|
Bio-Rad Laboratories, Inc. Class A (a)
|
140,000
|
75,290,600
|
|
Bruker Corp.
|
1,600,000
|
99,968,000
|
|
Charles River Laboratories International, Inc. (a)
|
385,000
|
90,120,800
|
|
Danaher Corp.
|
1,780,000
|
469,599,600
|
|
Lonza Group AG
|
160,000
|
96,464,928
|
|
Maravai LifeSciences Holdings, Inc. (a)
|
844,548
|
26,307,670
|
|
Olink Holding AB ADR (a)(b)
|
1,200,000
|
14,112,000
|
|
Quanterix Corp. (a)
|
500,000
|
8,430,000
|
|
Sartorius Stedim Biotech
|
76,299
|
26,301,555
|
|
Seer, Inc. (a)
|
907,959
|
8,062,676
|
|
Stevanato Group SpA
|
1,080,000
|
17,442,000
|
|
Thermo Fisher Scientific, Inc.
|
700,000
|
397,299,000
|
|
West Pharmaceutical Services, Inc.
|
320,000
|
99,321,600
|
|
1,620,262,179
|
|||
Personal Products - 0.4%
|
|||
Personal Products - 0.4%
|
|||
The Beauty Health Co. (a)(b)
|
799,005
|
11,401,801
|
|
The Beauty Health Co. (a)(e)
|
1,800,000
|
25,686,000
|
|
37,087,801
|
|||
Pharmaceuticals - 14.4%
|
|||
Pharmaceuticals - 14.4%
|
|||
Arvinas Holding Co. LLC (a)
|
700,000
|
29,183,000
|
|
AstraZeneca PLC (United Kingdom)
|
1,020,000
|
134,807,077
|
|
Bristol-Myers Squibb Co.
|
1,900,000
|
143,355,000
|
|
Eli Lilly & Co.
|
1,500,000
|
470,160,000
|
|
Merck & Co., Inc.
|
595,000
|
54,757,850
|
|
Pharvaris BV (a)
|
620,000
|
10,986,400
|
|
Roche Holding AG (participation certificate)
|
340,000
|
115,868,986
|
|
Royalty Pharma PLC
|
4,280,000
|
176,079,200
|
|
Theseus Pharmaceuticals, Inc.
|
600,000
|
4,050,000
|
|
UCB SA
|
240,000
|
21,168,688
|
|
1,160,416,201
|
|||
Specialty Retail - 0.2%
|
|||
Specialty Stores - 0.2%
|
|||
Warby Parker, Inc. (a)(b)
|
1,040,000
|
17,659,200
|
|
TOTAL COMMON STOCKS
(Cost $5,943,284,968)
|
7,931,264,935
|
||
Preferred Stocks - 1.2%
|
|||
Shares
|
Value ($)
|
||
Convertible Preferred Stocks - 1.1%
|
|||
Biotechnology - 0.5%
|
|||
Biotechnology - 0.5%
|
|||
Asimov, Inc. Series B (e)(f)
|
101,438
|
6,201,919
|
|
Caris Life Sciences, Inc. Series D (e)(f)
|
3,206,021
|
17,761,356
|
|
Element Biosciences, Inc. Series C (e)(f)
|
572,265
|
7,817,140
|
|
ElevateBio LLC Series C (a)(e)(f)
|
254,900
|
1,165,658
|
|
Inscripta, Inc. Series E (a)(e)(f)
|
1,282,228
|
7,795,946
|
|
40,742,019
|
|||
Health Care Providers & Services - 0.0%
|
|||
Health Care Services - 0.0%
|
|||
dMed Biopharmaceutical Co. Ltd. Series C (a)(e)(f)
|
380,451
|
2,739,247
|
|
Health Care Technology - 0.4%
|
|||
Health Care Technology - 0.4%
|
|||
Aledade, Inc.:
|
|||
Series B1(e)(f)
|
201,220
|
10,022,768
|
|
Series E1(e)(f)
|
56,664
|
2,822,434
|
|
Omada Health, Inc. Series E (e)(f)
|
2,153,073
|
12,908,103
|
|
Wugen, Inc. Series B (e)(f)
|
454,342
|
1,967,301
|
|
27,720,606
|
|||
Pharmaceuticals - 0.2%
|
|||
Pharmaceuticals - 0.2%
|
|||
Aristea Therapeutics, Inc. Series B (a)(e)(f)
|
1,037,400
|
9,896,796
|
|
Galvanize Therapeutics Series B (e)(f)
|
3,696,429
|
6,399,575
|
|
16,296,371
|
|||
TOTAL CONVERTIBLE PREFERRED STOCKS
|
87,498,243
|
||
Nonconvertible Preferred Stocks - 0.1%
|
|||
Diversified Financial Services - 0.1%
|
|||
Other Diversified Financial Services - 0.1%
|
|||
Thriveworks TopCo LLC Series B (e)(f)(g)
|
473,270
|
13,584,368
|
|
TOTAL PREFERRED STOCKS
(Cost $117,595,657)
|
101,082,611
|
||
Money Market Funds - 3.4%
|
|||
Shares
|
Value ($)
|
||
Fidelity Cash Central Fund 0.82% (h)
|
29,400,206
|
29,406,086
|
|
Fidelity Securities Lending Cash Central Fund 0.82% (h)(i)
|
241,556,218
|
241,580,374
|
|
TOTAL MONEY MARKET FUNDS
(Cost $270,984,710)
|
270,986,460
|
||
TOTAL INVESTMENT IN SECURITIES - 102.9%
(Cost $6,331,865,335)
|
8,303,334,006
|
NET OTHER ASSETS (LIABILITIES) - (2.9)%
|
(236,489,688)
|
NET ASSETS - 100.0%
|
8,066,844,318
|
(a)
|
Non-income producing
|
(b)
|
Security or a portion of the security is on loan at period end.
|
(c)
|
Security exempt from registration under Rule 144A of the Securities Act of 1933. These securities may be resold in transactions exempt from registration, normally to qualified institutional buyers. At the end of the period, the value of these securities amounted to $74,319,936 or 0.9% of net assets.
|
(d)
|
Affiliated company
|
(e)
|
Restricted securities (including private placements) - Investment in securities not registered under the Securities Act of 1933 (excluding 144A issues). At the end of the period, the value of restricted securities (excluding 144A issues) amounted to $146,884,166 or 1.8% of net assets.
|
(f)
|
Level 3 security
|
(g)
|
Investment is owned by a wholly-owned subsidiary (Subsidiary) that is treated as a corporation for U.S. tax purposes.
|
(h)
|
Affiliated fund that is generally available only to investment companies and other accounts managed by Fidelity Investments. The rate quoted is the annualized seven-day yield of the fund at period end. A complete unaudited listing of the fund's holdings as of its most recent quarter end is available upon request. In addition, each Fidelity Central Fund's financial statements are available on the SEC's website or upon request.
|
(i)
|
Investment made with cash collateral received from securities on loan.
|
Additional information on each restricted holding is as follows:
|
||
Security
|
Acquisition Date
|
Acquisition Cost ($)
|
Aledade, Inc. Series B1
|
5/07/21
|
7,704,855
|
Aledade, Inc. Series E1
|
5/20/22
|
2,822,683
|
Aristea Therapeutics, Inc. Series B
|
10/06/20
|
5,719,912
|
Asimov, Inc. Series B
|
10/29/21
|
9,401,345
|
Caris Life Sciences, Inc. Series D
|
5/11/21
|
25,968,770
|
dMed Biopharmaceutical Co. Ltd. Series C
|
12/01/20
|
5,403,602
|
Element Biosciences, Inc. Series C
|
6/21/21
|
11,763,880
|
ElevateBio LLC Series C
|
3/09/21
|
1,069,306
|
Galvanize Therapeutics Series B
|
3/29/22
|
6,399,572
|
Inscripta, Inc. Series E
|
3/30/21
|
11,322,073
|
Omada Health, Inc. Series E
|
12/22/21
|
12,908,103
|
The Beauty Health Co.
|
12/08/20
|
18,000,000
|
The Oncology Institute, Inc.
|
6/28/21
|
22,325,810
|
Thriveworks TopCo LLC Series B
|
7/23/21 - 2/25/22
|
13,588,179
|
Wugen, Inc. Series B
|
7/09/21
|
3,523,377
|
Affiliate
|
Value,
beginning
of period ($)
|
Purchases ($)
|
Sales
Proceeds ($)
|
Dividend
Income ($)
|
Realized
Gain (loss) ($)
|
Change in
Unrealized
appreciation
(depreciation) ($)
|
Value,
end
of period ($)
|
%ownership,
end
of period
|
Fidelity Cash Central Fund 0.82%
|
36,264,694
|
244,599,796
|
251,458,404
|
34,673
|
-
|
-
|
29,406,086
|
0.1%
|
Fidelity Securities Lending Cash Central Fund 0.82%
|
202,861,851
|
359,487,241
|
320,768,718
|
721,653
|
-
|
-
|
241,580,374
|
0.6%
|
Total
|
239,126,545
|
604,087,037
|
572,227,122
|
756,326
|
-
|
-
|
270,986,460
|
Affiliate
|
Value,
beginning
of period ($)
|
Purchases ($)
|
Sales
Proceeds ($)
|
Dividend
Income ($)
|
Realized
Gain (loss) ($)
|
Change in
Unrealized
appreciation
(depreciation) ($)
|
Value,
end
of period ($)
|
Zai Lab Ltd.
|
26,625,199
|
3,695,466
|
-
|
-
|
-
|
(11,282,027)
|
19,038,638
|
Total
|
26,625,199
|
3,695,466
|
-
|
-
|
-
|
(11,282,027)
|
19,038,638
|